Payment overview · 2025
General Payments
$2,891.59
150 reported records · 31 companies
Healthcare provider profile · identity verified
Thomas C Keller, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · HANOVER, PA · NPI 1073587515
Verified facts
What the public records show
CMS Open Payments records show Thomas C Keller, D.O. received $2,891.59 in general payments during 2025 across 150 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 934 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 934 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $368.71 | 12.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $352.32 | 12.2% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $279.40 | 9.7% | 14 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $207.98 | 7.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $178.66 | 6.2% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.99 | 5.7% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $153.46 | 5.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.05 | 5.1% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.17 | 3.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.25 | 3.2% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $79.60 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.87 | 2.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $72.82 | 2.5% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $71.27 | 2.5% | 4 | 2025 |
| Prescient Lab Services, LLC | Unresolved — no canonical attribution shown | $58.44 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.00 | 1.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.05 | 1.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.94 | 1.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.02 | 1.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.53 | 1.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.77 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.28 | 1.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.01 | 1.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.96 | 0.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.65 | 0.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.31 | 0.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.10 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.22 | 0.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $16.08 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.36 | 0.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.32 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,849.09 | 149 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $210.86 | 7 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $207.98 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.51 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $179.34 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $159.31 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $158.19 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.34 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $145.61 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.30 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $131.07 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.49 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $99.27 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.17 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.83 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $94.51 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $93.25 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.91 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $87.54 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.23 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $79.60 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $77.08 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $72.82 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $72.82 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71.27 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $62.82 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $62.82 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $62.82 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.95 | 2 | 2025 |
Source payment records
|
|||||
| AVERTD AMPLIFICATION MIX Normalized: avertd amplification mix |
Device | Prescient Lab Services, LLC | $58.44 | 1 | 2025 |
Source payment records
|
|||||
| AVERTD BIOFILMCHIP MICROARRAY MAGAZINE Normalized: avertd biofilmchip microarray magazine |
Device | Prescient Lab Services, LLC | $58.44 | 1 | 2025 |
Source payment records
|
|||||
| AVERTD INTELLIPAC REAGENT MODULE Normalized: avertd intellipac reagent module |
Device | Prescient Lab Services, LLC | $58.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.00 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.02 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.15 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $12.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 12 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 934 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
108 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
934 | 93 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
934 | 93 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2181 | 265 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1795 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 1456 | 222 |
| Furosemide | Furosemide | 1257 | 107 |
| Gabapentin | Gabapentin | 1031 | 101 |
| Sertraline Hcl | Sertraline Hcl | 996 | 66 |
| Eliquis | Apixaban | 934 | 93 |
| Omeprazole | Omeprazole | 895 | 134 |
| Lisinopril | Lisinopril | 877 | 132 |
| Metoprolol Tartrate | Metoprolol Tartrate | 843 | 71 |
| Losartan Potassium | Losartan Potassium | 811 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 715 | 83 |
| Metformin Hcl | Metformin Hcl | 687 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 679 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 664 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 656 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 638 | 65 |
| Potassium Chloride | Potassium Chloride | 563 | 54 |
| Trazodone Hcl | Trazodone Hcl | 530 | 66 |
| Famotidine | Famotidine | 506 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 85 |
| Simvastatin | Simvastatin | 444 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 431 | 33 |
| Carvedilol | Carvedilol | 430 | 72 |
| Divalproex Sodium | Divalproex Sodium | 413 | 21 |
| Donepezil Hcl | Donepezil Hcl | 400 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 391 | 35 |
| Finasteride | Finasteride | 319 | 22 |
| Spironolactone | Spironolactone | 303 | 20 |
| Mirtazapine | Mirtazapine | 268 | 30 |
| Prednisone | Prednisone | 263 | 43 |
| Allopurinol | Allopurinol | 262 | 27 |
| Memantine Hcl | Memantine Hcl | 258 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 246 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 242 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 213 | 21 |
| Montelukast Sodium | Montelukast Sodium | 208 | 28 |
| Warfarin Sodium | Warfarin Sodium | 199 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 46 |
| Bumetanide | Bumetanide | 182 | 13 |
| Levetiracetam | Levetiracetam | 165 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 162 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 162 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 154 | 15 |
| Meloxicam | Meloxicam | 153 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 152 | 19 |
| Meclizine Hcl | Meclizine Hcl | 152 | 28 |
| Risperidone | Risperidone | 152 | suppressed |
| Atenolol | Atenolol | 148 | 18 |
| Januvia | Sitagliptin Phosphate | 140 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 139 | 13 |
| Lorazepam | Lorazepam | 136 | 46 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 133 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 133 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 131 | suppressed |
| Valsartan | Valsartan | 128 | suppressed |
| Ramipril | Ramipril | 127 | suppressed |
| Xarelto | Rivaroxaban | 127 | 19 |
| Baclofen | Baclofen | 126 | 15 |
| Tramadol Hcl | Tramadol Hcl | 124 | 34 |
| Ezetimibe | Ezetimibe | 121 | 19 |
| Glimepiride | Glimepiride | 120 | 19 |
| Buspirone Hcl | Buspirone Hcl | 115 | 11 |
| Myrbetriq | Mirabegron | 108 | 11 |
| Glipizide | Glipizide | 106 | 13 |
| Methylprednisolone | Methylprednisolone | 105 | 83 |
| Olanzapine | Olanzapine | 105 | suppressed |
| Jardiance | Empagliflozin | 103 | 27 |
| Bupropion Hcl | Bupropion Hcl | 100 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 100 | 12 |
| Ozempic | Semaglutide | 99 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 97 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 96 | 15 |
| Aripiprazole | Aripiprazole | 93 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Synthroid | Levothyroxine Sodium | 89 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 41 |
| Nystatin | Nystatin | 86 | 39 |
| Irbesartan | Irbesartan | 85 | 23 |
| Latanoprost | Latanoprost | 80 | 11 |
| Metformin Hcl Er | Metformin Hcl | 77 | 16 |
| Chlorthalidone | Chlorthalidone | 76 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 76 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 15 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 14 |
| Amoxicillin | Amoxicillin | 67 | 37 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 66 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 66 | suppressed |
| Sotalol | Sotalol Hcl | 64 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 62 | suppressed |
| Rytary | Carbidopa/Levodopa | 62 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 61 | suppressed |
| Repaglinide | Repaglinide | 60 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 59 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 58 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 58 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 57 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 57 | 19 |
| Anastrozole | Anastrozole | 56 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 56 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 56 | suppressed |
| Azithromycin | Azithromycin | 55 | 48 |
| Alendronate Sodium | Alendronate Sodium | 54 | 14 |
| Celecoxib | Celecoxib | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 53 | suppressed |
| Perphenazine | Perphenazine | 53 | suppressed |
| Amantadine | Amantadine Hcl | 52 | suppressed |
| Nadolol | Nadolol | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | 11 |
| Loperamide | Loperamide Hcl | 48 | 19 |
| Methotrexate | Methotrexate Sodium | 48 | suppressed |
| Dutasteride | Dutasteride | 47 | suppressed |
| Cilostazol | Cilostazol | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Fluocinonide | Fluocinonide | 45 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Rexulti | Brexpiprazole | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | 12 |
| Nexium | Esomeprazole Magnesium | 42 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 41 | 35 |
| Ondansetron Odt | Ondansetron | 41 | 20 |
| Nyamyc | Nystatin | 40 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 19 |
| Enulose | Lactulose | 38 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Budesonide | Budesonide | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Alprazolam | Alprazolam | 32 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 17 |
| Potassium Citrate Er | Potassium Citrate | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 25 |
| Fluconazole | Fluconazole | 26 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Prolia | Denosumab | 26 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | 11 |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,891.59 · 150 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AMPYRA, AREXVY, AUSTEDO XR, AVERTD AMPLIFICATION MIX, AVERTD BIOFILMCHIP MICROARRAY MAGAZINE, AVERTD INTELLIPAC REAGENT MODULE, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, Fluad, Flucelvax, GARDASIL 9, GEMTESA, INBRIJA, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Nimbl, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error